Nifty
Sensex
:
:
11745.30
40043.38
-144.10 (-1.21%)
-478.72 (-1.18%)

Pharmaceuticals & Drugs - Domestic

Rating :
57/99  (View)

BSE: 531349 | NSE: PANACEABIO

178.40
-1.15 (-0.64%)
28-Oct-2020 | 1:29PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  180.00
  •  181.00
  •  177.10
  •  179.55
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  23868
  •  42.58
  •  263.35
  •  85.95

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,099.45
  • N/A
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,722.47
  • N/A
  • 6.64

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 73.59%
  • 9.15%
  • 14.89%
  • FII
  • DII
  • Others
  • 0.05%
  • 1.28%
  • 1.04%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -6.56
  • -7.85
  • -5.66

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -6.35
  • -
  • -

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -3.91
  • -9.41
  • -4.99

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 9.85
  • 12.79
  • 10.04

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Net Sales
133
126
6%
125
120
5%
168
110
52%
125
120
4%
Expenses
110
102
8%
148
260
-43%
131
85
54%
131
130
1%
EBITDA
23
23
-4%
-23
-140
-
37
26
44%
-6
-10
-
EBIDTM
17%
19%
-18%
-117%
22%
23%
-5%
-8%
Other Income
1
5
-76%
18
2
703%
3
3
-2%
3
2
102%
Interest
45
41
11%
44
24
85%
47
-14
-
41
29
41%
Depreciation
11
11
0%
10
13
-22%
11
52
-79%
11
14
-18%
PBT
-33
-24
-
-59
186
-
-18
-9
-
-70
-99
-
Tax
0
3
-88%
9
3
248%
2
5
-53%
2
-2
-
PAT
-33
-27
-
-69
184
-
-20
-14
-
-73
-96
-
PATM
-25%
-21%
-55%
153%
-12%
-13%
-58%
-80%
EPS
-5.41
-4.34
-
-11.18
29.94
-
-3.30
-2.26
-
-11.88
-15.68
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
551
457
593
544
653
687
510
608
710
1,168
900
Net Sales Growth
16%
-23%
9%
-17%
-5%
35%
-16%
-14%
-39%
30%
 
Cost Of Goods Sold
168
172
187
150
216
280
214
263
348
534
472
Gross Profit
383
284
406
394
437
407
296
345
363
634
428
GP Margin
69%
62%
68%
73%
67%
59%
58%
57%
51%
54%
48%
Total Expenditure
521
590
508
497
541
643
592
695
796
899
788
Power & Fuel Cost
-
35
34
31
25
31
32
38
29
23
13
% Of Sales
-
8%
6%
6%
4%
4%
6%
6%
4%
2%
1%
Employee Cost
-
147
152
148
142
136
145
147
161
143
97
% Of Sales
-
32%
26%
27%
22%
20%
28%
24%
23%
12%
11%
Manufacturing Exp.
-
44
40
42
39
44
53
67
51
45
96
% Of Sales
-
10%
7%
8%
6%
6%
10%
11%
7%
4%
11%
General & Admin Exp.
-
43
40
53
39
57
60
73
75
94
61
% Of Sales
-
9%
7%
10%
6%
8%
12%
12%
11%
8%
7%
Selling & Distn. Exp.
-
31
37
38
44
44
46
49
58
48
42
% Of Sales
-
7%
6%
7%
7%
6%
9%
8%
8%
4%
5%
Miscellaneous Exp.
-
117
18
36
35
51
42
57
75
12
42
% Of Sales
-
26%
3%
7%
5%
7%
8%
9%
11%
1%
1%
EBITDA
31
-133
85
47
112
44
-82
-86
-86
268
112
EBITDA Margin
6%
-29%
14%
9%
17%
6%
-16%
-14%
-12%
23%
12%
Other Income
26
5
8
47
20
28
15
5
9
16
94
Interest
178
105
101
101
127
105
150
104
101
56
43
Depreciation
43
55
59
68
73
67
71
86
77
75
50
PBT
-181
-288
-66
-75
-69
-99
-288
-270
-255
154
113
Tax
14
9
10
-11
2
3
2
-19
-54
22
40
Tax Rate
-8%
19%
-15%
16%
-10%
-3%
-2%
7%
21%
14%
36%
PAT
-195
38
-74
-55
-19
-101
-112
-234
-201
132
72
PAT before Minority Interest
-195
38
-76
-56
-21
-102
-113
-234
-201
132
72
Minority Interest
0
0
2
2
2
2
1
0
0
0
0
PAT Margin
-35%
8%
-13%
-10%
-3%
-15%
-22%
-39%
-28%
11%
8%
PAT Growth
-515%
151%
-35%
-196%
82%
10%
52%
-16%
-252%
83%
 
EPS
-31.77
6.13
-12.10
-8.93
-3.02
-16.43
-18.20
-38.22
-32.81
21.61
11.81

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
350
309
356
449
471
513
626
875
654
701
Share Capital
6
6
6
22
22
6
6
6
6
7
Total Reserves
344
303
350
426
449
507
620
869
648
694
Non-Current Liabilities
70
591
719
1,100
918
767
865
720
503
778
Secured Loans
8
560
705
866
722
582
688
510
422
508
Unsecured Loans
38
10
9
1
1
1
2
3
2
199
Long Term Provisions
40
27
18
184
180
180
171
171
3
0
Current Liabilities
938
696
689
475
706
827
510
517
576
332
Trade Payables
270
277
249
188
209
252
176
122
97
147
Other Current Liabilities
585
242
238
94
195
252
50
135
102
6
Short Term Borrowings
69
165
191
192
296
321
274
250
364
0
Short Term Provisions
14
11
12
2
6
2
10
10
13
178
Total Liabilities
1,356
1,592
1,774
2,025
2,099
2,112
2,008
2,119
1,734
1,815
Net Block
806
949
1,001
1,071
1,144
1,276
1,154
1,195
685
691
Gross Block
1,393
1,606
1,600
1,620
1,633
1,698
1,694
1,639
1,040
974
Accumulated Depreciation
587
657
599
549
489
422
540
444
355
282
Non Current Assets
848
1,028
1,071
1,475
1,573
1,739
1,574
1,617
920
936
Capital Work in Progress
23
40
30
116
110
117
135
91
119
162
Non Current Investment
5
5
7
5
10
16
17
31
57
73
Long Term Loans & Adv.
13
28
22
237
262
275
266
294
57
0
Other Non Current Assets
1
5
10
1
1
0
2
7
3
0
Current Assets
508
565
703
549
526
373
434
501
814
879
Current Investments
0
2
0
4
5
0
6
2
0
0
Inventories
81
334
316
305
310
220
268
385
411
458
Sundry Debtors
89
136
142
142
99
95
70
68
276
108
Cash & Bank
23
23
14
23
52
25
39
16
49
47
Other Current Assets
314
10
175
9
60
33
51
31
78
267
Short Term Loans & Adv.
41
59
56
67
50
25
44
19
71
263
Net Current Assets
-430
-131
14
75
-180
-454
-76
-15
238
547
Total Assets
1,356
1,592
1,774
2,025
2,099
2,112
2,008
2,119
1,734
1,815

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
105
118
131
91
37
54
-24
228
78
62
PBT
46
-66
-67
-19
-99
-111
-253
-255
154
113
Adjustment
-70
167
150
149
167
60
161
200
72
-42
Changes in Working Capital
127
21
43
-58
-25
107
68
288
-127
4
Cash after chg. in Working capital
103
122
126
72
43
56
-24
233
99
75
Interest Paid
0
0
0
0
0
0
0
0
0
0
Tax Paid
2
-4
5
19
-6
-2
0
-5
-21
-13
Other Direct Exp. Paid
0
0
0
0
0
0
0
0
0
0
Extra & Other Items
0
0
0
0
0
0
0
0
0
0
Cash From Investing Activity
-5
55
-26
16
-37
-38
-61
-124
12
-117
Net Fixed Assets
763
-15
-27
12
-29
-5
-31
-482
-30
-60
Net Investments
342
0
50
0
0
-122
-13
-26
-7
-9
Others
-1,110
70
-48
5
-7
90
-16
384
49
-48
Cash from Financing Activity
-101
-164
-107
-117
-1
-30
105
-134
-85
28
Net Cash Inflow / Outflow
-2
9
-2
-10
-1
-14
20
-29
5
-27
Opening Cash & Equivalents
16
7
10
20
21
35
15
44
40
68
Closing Cash & Equivalent
14
16
7
10
20
21
35
15
44
40

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
57
50
58
-4
-1
14
34
73
107
105
ROA
3%
-5%
-3%
-1%
-5%
-5%
-11%
-10%
7%
4%
ROE
11%
-23%
-34%
0%
-253%
-76%
-71%
-37%
20%
11%
ROCE
13%
3%
3%
10%
0%
3%
-12%
-11%
14%
11%
Fixed Asset Turnover
0.30
0.37
0.35
0.40
0.41
0.30
0.37
0.53
1.16
0.96
Receivable days
90
85
93
67
51
59
41
88
60
46
Inventory Days
166
199
203
172
141
174
196
204
136
184
Payable days
214
187
164
131
137
149
83
57
38
28
Cash Conversion Cycle
42
98
132
108
55
84
154
235
157
203
Total Debt/Equity
1.85
3.05
2.79
-100.22
93.42
12.38
4.69
1.96
1.32
1.01
Interest Cover
1
0
0
1
0
0
-1
-2
4
4

News Update


  • Panacea Biotec gets warning letter from USFDA for Baddi plant
    5th Oct 2020, 11:33 AM

    The company has received warning letter for violating current good manufacturing practice norms

    Read More
  • Panacea Biotec completes Phase 1/11 study to evaluate safety, immunogenicity of DengiAll
    24th Sep 2020, 13:15 PM

    With more than 3.9 billion people living in Dengue endemic areas and over 390 million infections per year, DengiAll targets a global market of over $3 billion

    Read More
  • Panacea Biotec terminates MoU with Refana for COVID-19 vaccine
    24th Aug 2020, 15:30 PM

    Termination is due to delays in project timelines and difficulty in moving ahead with the joint venture

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.